Esreboxetine compared with placebo for adults with fibromyalgia
Tests esreboxetine against placebo in adults living with fibromyalgia.
Key facts
- Who runs it
- Axsome Therapeutics, Inc.
- Where
- Anaheim, Atlanta, Austin, Boston, Brooklyn, Charleston, Chicago, Cranston, Cromwell, Dallas, Duncansville, Glendale, Hartsdale, Hazelwood, High Point, Hollywood, Houston, Huber Heights, Jacksonville, Kansas City, Knoxville, Lakeland, Las Vegas, Little Rock, Louisville, Maitland, Marietta, Memphis, Milford, Norcross, North Dartmouth, Oceanside, Orlando, Overland Park, Phoenix, Plymouth Meeting, Prairieville, Prosper, Redlands, Rockville, Sacramento, San Antonio, Santa Ana, Springfield, Tampa, The Villages, The Woodlands, Tinley Park, Town and Country, Tucson, Tulsa, Watertown, and Williamsville, United StatesSee the 53 sites
- Trial code
- Registry title
- Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 620 people, planned
- Started
- 14 Jan 2026
- Expected to end
- Mar 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- AXS-14 (Esreboxetine)
- Placebo
- Record updated
- 10 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with fibromyalgia. It tests AXS-14 (esreboxetine) against a placebo (a dummy pill).
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Fibromyalgia as the main diagnosis, based on the 2016 ACR diagnostic criteria.
- Earlier treatment
- People cannot join if they were in an earlier trial with reboxetine or esreboxetine, or now take reboxetine.
Main reasons for not taking part
- Earlier participation in a clinical trial with reboxetine or esreboxetine
- Currently receiving reboxetine for any condition
- Unable to follow the study procedures
- The study doctor judges that joining is not medically appropriate
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Has a primary diagnosis of fibromyalgia based on the 2016 ACR diagnostic criteria
- Male or female, ≥18 years of age
- Provides written informed consent to participate in the study before conducting any study procedures
Who cannot take part
- Previous participation in a clinical trial with reboxetine or esreboxetine or currently receiving treatment with reboxetine for any condition
- Unable to comply with study procedures
- Medically inappropriate for study participation in the opinion of the investigator
Where in United States
- Anaheim, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
- Atlanta, GeorgiaHospital not named in the registryContact: Study DirectorTaking people
- Austin, TexasHospital not named in the registryContact: Study DirectorTaking people
- Boston, MassachusettsHospital not named in the registryContact: Study DirectorTaking people
- Brooklyn, New YorkHospital not named in the registryContact: Study DirectorTaking people
- Charleston, South CarolinaHospital not named in the registryContact: Study DirectorTaking people
- Chicago, IllinoisHospital not named in the registryContact: Study DirectorTaking people
- Cranston, Rhode IslandHospital not named in the registryContact: Study DirectorTaking people
- Cromwell, ConnecticutHospital not named in the registryContact: Study DirectorTaking people
- Dallas, TexasHospital not named in the registryContact: Study DirectorTaking people
- Duncansville, PennsylvaniaHospital not named in the registryContact: Study DirectorTaking people
- Glendale, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
- Hartsdale, New YorkHospital not named in the registryContact: Study DirectorTaking people
- Hazelwood, MissouriHospital not named in the registryContact: Study DirectorTaking people
- High Point, North CarolinaHospital not named in the registryContact: Study DirectorTaking people
- Hollywood, FloridaHospital not named in the registryContact: Study DirectorTaking people
- Houston, TexasHospital not named in the registryContact: Study DirectorTaking people
- Huber Heights, OhioHospital not named in the registryContact: Study DirectorTaking people
- Jacksonville, FloridaHospital not named in the registryContact: Study DirectorTaking people
- Kansas City, KansasHospital not named in the registryContact: Study DirectorTaking people
- Knoxville, TennesseeHospital not named in the registryContact: Study DirectorTaking people
- Lakeland, FloridaHospital not named in the registryContact: Study DirectorTaking people
- Las Vegas, NevadaHospital not named in the registryContact: Study DirectorTaking people
- Little Rock, ArkansasHospital not named in the registryContact: Study DirectorTaking people
- Louisville, KentuckyHospital not named in the registryContact: Study DirectorTaking people
- Maitland, FloridaHospital not named in the registryContact: Study DirectorTaking people
- Marietta, GeorgiaHospital not named in the registryContact: Study DirectorTaking people
- Memphis, TennesseeHospital not named in the registryContact: Study DirectorTaking people
- Milford, OhioHospital not named in the registryContact: Study DirectorTaking people
- Norcross, GeorgiaHospital not named in the registryContact: Study DirectorTaking people
- North Dartmouth, MassachusettsHospital not named in the registryContact: Study DirectorTaking people
- Oceanside, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
- Orlando, FloridaHospital not named in the registryContact: Study DirectorTaking people
- Overland Park, KansasHospital not named in the registryContact: Study DirectorTaking people
- Phoenix, ArizonaHospital not named in the registryContact: Study DirectorTaking people
- Plymouth Meeting, PennsylvaniaHospital not named in the registryContact: Study DirectorTaking people
- Prairieville, LouisianaHospital not named in the registryContact: Study DirectorTaking people
- Prosper, TexasHospital not named in the registryContact: Study DirectorTaking people
- Redlands, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
- Rockville, MarylandHospital not named in the registryContact: Study DirectorTaking people
- Sacramento, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
- San Antonio, TexasHospital not named in the registryContact: Study DirectorTaking people
- Santa Ana, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
- Springfield, MassachusettsHospital not named in the registryContact: Study DirectorTaking people
- Tampa, FloridaHospital not named in the registryContact: Study DirectorTaking people
- The Villages, FloridaHospital not named in the registryContact: Study DirectorTaking people
- The Woodlands, TexasHospital not named in the registryContact: Study DirectorTaking people
- Tinley Park, IllinoisHospital not named in the registryContact: Study DirectorTaking people
- Town and Country, MissouriHospital not named in the registryContact: Study DirectorTaking people
- Tucson, ArizonaHospital not named in the registryContact: Study DirectorTaking people
- Tulsa, OklahomaHospital not named in the registryContact: Study DirectorTaking people
- Watertown, MassachusettsHospital not named in the registryContact: Study DirectorTaking people
- Williamsville, New YorkHospital not named in the registryContact: Study DirectorTaking people
About the trial
What the trial wants to find out
The study is a Phase 3, double-blind, placebo-controlled, randomized withdrawal study to assess the efficacy and safety of AXS-14 in the management of fibromyalgia.
The 2 groups in the trial
- AXS-14 (esreboxetine)Treatment being tested
* Up to 12 weeks in the open-label period; * Up to 12 weeks in the randomized double-blind period (if applicable)
- PlaceboPlacebo, for comparison
• Up to 12 weeks in the randomized double-blind period (if applicable)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Assess the Efficacy and Safety of AXS-14 in the Management of Fibromyalgia
- Plain-language title
- Esreboxetine compared with placebo for adults with fibromyalgiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 10 November 2026